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with intermittent or continuous discharge of chyle from
cutaneous vesicles in the perineum, scrotum, labia, or the
legs, interfering greatly with quality of life. The ruptured
lymphatic vesicles also serve as an entry point for bacteria
causing cellulitis or lymphangitis. Rupture of mesenteric
lymphatics results in chylous ascites, and rupture of lym-
phatics into the lumen of the bowel causes protein-losing
enteropathy.6 Patients with lymphangiectasia and lym-
phatic valvular incompetence may also have reflux into the
renal pelvis, with ruptured lymphatics causing chyluria.7
Primary chylothorax can develop as a result of rupture of
the dilated thoracic duct, with or without proximal occlu-
sion, or as a result of rupture of diaphragmatic or inter-
costal lymphatic collaterals, or as a result of pulmonary
lymphangiomyomatosis. Chyloptysis results from rupture
of the dilated, refluxing thoracic lymphatics into the tra-
cheobronchial tree.8
PCDs are distinguished from secondary chylous disor-
ders caused by iatrogenic injury or malignancy because the
Primary chylous disorders (PCDs) are most frequently
caused by congenital lymphangiectasia, with or without
associated thoracic duct obstruction. The valves in the
dilated, varicose lymph vessels (megalymphatics) become
incompetent and lymph mixed with chyle refluxes into the
lower limbs or the genitalia.1-4 Reflux causes delayed lym-
phatic transport in the affected leg and chronic lym-
phedema frequently develops.5 These patients present
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Purpose: Primary chylous disorders (PCDs) are rare. Rupture of dilated lymph vessels (lymphangiectasia) may result in
chylous ascites, chylothorax, or leakage of chyle through chylocutanous fistulas in the lower limbs or genitalia. Chyle
may reflux through incompetent lymphatics, causing lymphedema. To assess the efficacy of surgical treatment, we
reviewed our experience.
Methods: The clinical data of 35 patients with PCDs treated between January 1, 1976, and August 31, 2000, were
reviewed retrospectively.
Results: Fifteen men and 20 women (mean age, 29 years; range, 1 day-81 years) presented with PCDs. Sixteen (46%)
patients had chylous ascites, and 19 (54%) had chylothorax (20 patients), and of these, 10 (29%) had both. In 16
patients, reflux of chyle into the pelvic or lower limb lymphatics caused lymphedema (14, 88%) or lymphatic leak
through cutaneous fistulae (11, 69%). Presenting symptoms included lower-limb edema (19, 54%), dyspnea (17, 49%),
scrotal or labial edema (15, 43%), or abdominal distention (13, 37%). Primary lymphangiectasia presented alone in 23
patients (66%), and it was associated with clinical syndromes or additional pathologic findings in 12 (yellow nail syn-
drome in 4, lymphangiomyomatosis in 3, unknown in 3, Prasad syndrome (hypogammaglobulinemia, lymphadenopa-
thy, and pulmonary insufficiency) in 1, and thoracic duct cyst in 1). Twenty-one (60%) patients underwent 26 surgical
procedures. Preoperative imaging included computed tomography scan in 15 patients, magnetic resonance imaging in
3, lymphoscintigraphy in 12, and lymphangiography in 14. Fifteen patients underwent 18 procedures for chylous
ascites or pelvic reflux. Ten (56%) procedures were resection of retroperitoneal/mesenteric lymphatics with or without
sclerotherapy of lymphatics, 4 (22%) were lymphovenous anastomoses or grafts, 3 (17%) were peritoneovenous shunts,
and 1 (6%) patient had a hysterectomy. Six patients underwent eight procedures for chylothorax, including thoraco-
tomy with decortication and pleurodesis (4 procedures), thoracoscopic decortication (1 patient), ligation of thoracic
duct (2 procedures), and resection of thoracic duct cyst (1 patient). Postoperative mean follow-up was 54 months
(range, 0.3-276). Early complications included wound infections in 3 patients, elevated liver enzymes in 1, and perito-
neovenous shunt occlusion with innominate vein occlusion in 1. All patients improved initially, but four (19%) had
recurrence of symptoms at a mean of 25 months (range, 1-43). Three patients had postoperative lymphoscintigraphy
confirming improved lymphatic transport and diminished reflux. One patient died 12 years postoperatively, from causes
unrelated to PCD.
Conclusions: More than half of the patients with PCDs require surgical treatment, and surgery should be considered in
patients with significant symptoms of PCD. Lymphangiography is recommended to determine anatomy and the site of
the lymphatic leak, especially if lymphovenous grafting is planned. All patients had initial benefit postoperatively and two
thirds of patients demonstrated durable clinical improvement after surgical treatment. (J Vasc Surg 2001;34:785-91.)
treatment strategies are somewhat different. Although
PCDs are treated primarily with medium-chain triglyc-
eride (MCT) diet and serial thoracentesis or paracentesis,
a select group of patients are candidates for surgical inter-
vention. To assess the results of treatment, we reviewed
our 24-year experience.
METHODS
Between July 1, 1976, and August 31, 2000, 36
patients with PCDs were treated at the Mayo Clinic. One
patient with chylothorax, treated with thoracic duct-
azygos vein anastomosis, declined to participate in
research study, and she was excluded from further analy-
sis of the data. Patients with secondary chylous effusions
caused by benign or malignant tumors, a history of
trauma, or previous operations suggesting iatrogenic injury
were also excluded. Clinical history and physical examina-
tion, including the confirmation of chylous ascites or chy-
lothorax based on examination of aspirated fluid, were
recorded retrospectively. The diagnosis of chylous effusion
was confirmed by two or more of the following evaluations:
appearance of milky fluid, triglyceride level >110 mL/dL,
and lipoprotein analysis for the presence of chylomicrons.
Sudan red staining for fat globules or a cholesterol/
triglyceride ratio of less than 1 are also diagnostic but were
not used in this patient series. Laboratory values were
reported as the mean ± standard deviation. Results of imag-
ing studies, including chest radiograph, lympho-
scintigraphy, lymphangiography, computed tomography
(CT), and magnetic resonance imaging (MRI) were
recorded, and films, when available, reviewed. Medical
management, surgical procedures, and complications were
recorded. Surgical treatment for chylous ascites included
resection of retroperitoneal and mesenteric lymphatics
with or without sclerotherapy of lymphatics, sclerotherapy
of the dilated lymphatics, lymphovenous anastomosis or
grafting, peritoneovenous shunt, or hysterectomy for peri-
uterine lymphangiectasia. Procedures for chylothorax were
thoracotomy with decortication and pleurodesis, (open or
thoracoscopically), thoracic duct ligation, or thoracic duct
cyst resection. Follow-up evaluation was obtained through
clinic visits or patient questionnaire.
Clinical outcome for patients with chylous effusions
was recorded based on the classification of Browse et al,4
as follows: cured, complete resolution of chylous effusion
or ascites and cessation of protein-losing enteropathy (if
present); improved, marked improvement in effusion or
chylous leak and quality of life and reduction of protein-
losing enteropathy; poor result, no change (or deteriora-
tion) in chylous leak and/or degradation of quality of life
over time.
RESULTS
Clinical characteristics. Thirty-five patients, 15 men
and 20 women, with a mean age of 29 years (range, 1 day-
81 years) were treated for PCDs. The 81-year–old patient
had lymphangiomyomatosis that had been treated symp-
tomatically elsewhere for many years with serial thoracen-
tesis. Presenting symptoms are summarized in Table I.
Sixteen patients (46%) had chylous ascites, 19 (54%) had
chylothorax, and 10 (29%) had both. Table II summarizes
the clinical findings. Of the 10 patients with both chylous
ascites and chylothorax, in 8 (80%) patients the chylous
ascites was more symptomatic, and 7 (70%) patients also
had chylous reflux into the lower extremity and/or per-
ineum (6 patients), or pericardium (1 patient).
Nine (26%) patients had chylous reflux in addition to
chylothorax or chylous ascites. Four patients (44%) had
reflux into both the extremity and the perineum, with one
patient in this group having chylous reflux into the knee
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Table I. Signs and symptoms of 35 patients with pri-
mary chylous disorders
Symptom No. of patients (%)
Lower-limb edema 19 (54)
Dyspnea 17 (49)
Scrotal or labial edema 15 (43)
Abdominal distention 13 (37)
Fig 1. CT scan of a 43-year–old woman demonstrating multiple
cystic lesions consistent with pulmonary lymphangiomyomatosis.
This film was performed after thoracentesis, and therefore the left
pleural effusion is not present.
Table II. Clinical findings of PCDs in 35 patients
Clinical finding No. of patients* (%)
Chylothorax 20 (57)
Chylous ascites 16 (46)
Chylorrhea of the perineum or genitalia 11 (31)





*Patients may have more than one clinical finding.
joint. Two (22%) patients had only labial or scrotal reflux,
2 (22%) had only extremity symptoms, and 1 (11%) had
chyluria. In addition, 5 patients (14%) had steatorrhea and
13 (37%) had hypoproteinemia (<6.3 g/dL) and/or
hypoalbuminemia (<3.5 g/dL). Mean total serum protein
and serum albumin for patients undergoing surgical inter-
vention was 5.6 ± 1.4 and 3.1 ± 1.0 g/dL, respectively.
Twenty-three patients (66%) had a diagnosis of pri-
mary lymphangiectasia alone, 4 (11%) had yellow nail syn-
drome, 3 (9%) had lymphangiomyomatosis, 1 (3%) had
Prasad syndrome (presenting as severe hypogammaglobu-
linemia, granulomatous lymphadenopathy, and pulmonary
insufficiency), 1 (3%) had a thoracic duct cyst in 1 (3%),
and the etiology was unknown in 3 patients (9%).
Diagnostic studies. Twenty-five patients underwent
CT imaging of the chest and/or abdomen during initial
evaluation. CT findings included ascites in 7 (28%)
patients, pleural effusion in 5 (20%), both pleural fluid and
ascites in 2 (8%), pulmonary lymphangiomyomatosis in 2
(8%) (Fig 1), and intestinal wall thickening in 1 (4%), and
CT scan was interpreted as normal in eight (32%) patients.
Of those 18 patients without CT imaging or with a
negative CT scan, diagnosis was based on chest radiograph
and diagnostic thoracentesis in 6 (33%), paracentesis in 1
(6%), MRI in 1 (6%), both lymphoscintigraphy and lym-
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phangiography in 7 (39%), lymphoscintigraphy alone in 1
(6%), and lymphangiogram alone in 2 (11%). Two patients
underwent MRI in addition to both lymphoscintigraphy
and lymphangiography.
Of the 21 patients who underwent surgical treatment
for PCD, 12 patients had preoperative lymphoscintigraphy
demonstrating reflux in 10 (83%) patients and lymphan-
giectasia in 6 (50%) patients (Fig 2). Fourteen patients had
preoperative lymphangiography, and of those, 10 patients
also had a lymphoscintigraphy. Lymphangiography showed
lymphangiectasia in 12 patients (86%), reflux in 10 (71%),
and evidence of effusion in 2 (21%) patients (Fig 3).
Nonoperative management. Nonoperative manage-
ment of patients with primary chylous disorders included
low-fat MCT diet to decrease chyle production, paracen-
tesis or thoracentesis to decompress the abdominal or tho-
racic effusion, diuretics, and compression garments to
reduce limb swelling. Antibiotics were given to patients
with cellulitis or lymphangitis.
Fourteen patients were managed with nonoperative
treatment alone, including two patients who declined sur-
gical intervention and 6 (43%) who were high-risk for sur-
gical treatment. Most patients received more than one
treatment method. Three (21%) patients were controlled
with serial paracentesis or thoracentesis, and one (7%)
patient had good relief of lower-extremity reflux with the
use of compression garments. Four (29%) patients were
managed with MCT diet alone, with adjunctive diuretics.
Although all patients were counseled in maintaining an
MCT diet, 11 of 14 (79%) patients were compliant with
an MCT, including two patients who required temporary
parenteral nutrition. Six (43%) patients were treated with
diuretics.
Fig 2. Lymphoscintigraphy after injection of technitium-99m
labeled colloid via left ankle. A, At 1 hour, transport of colloid to
left groin is visualized. B, At 6 hours, complete reflux of lymphat-
ics extending across the pelvis and continuing to the right ankle.
Fig 3. Lymphangiogram with lymphangiectasia and reflux. A,
After injection of contrast via left lower limb, visualization of
dilated pelvic lymphatics and filling of contralateral pelvic and
retroperitoneal lymphatics. B, Right ankle with lymphangiogra-
phy contrast caused by reflux after injection of left limb.
A B A B
Mean follow-up for patients treated medically was 51
months (range, 0-210 months), but eight patients were
lost to follow-up. Of the remaining six patients, based on
Browse et al’s4 classification, 2 (33%) were cured, 1 (17%)
was improved, and 3 (50%) were the same or worse. One
patient, who had improvement after 48 months, died of
causes unrelated to PCD.
Surgical treatment and follow-up. Twenty-six surgi-
cal procedures were performed on 21 (60%) patients.
Eighteen procedures were performed for chylous ascites or
reflux in 15 patients. The surgical treatment for chylous
ascites or reflux included resection of retroperitoneal and
mesenteric lymphatics with or without sclerotherapy of lym-
phatics in seven (47%) patients, with three patients under-
going contralateral treatment in a staged manner. This
treatment was reserved for patients who were good surgical
candidates. Sclerotherapy of the dilated lymphatics was
done with a tetracycline solution, 500 to 1000 mg diluted
in 20 mL of normal saline and injected directly into the
dilated retroperitoneal lymph vessels to provoke obstructive
lymphangitis. Four (27%) patients had lymphovenous anas-
tomosis (2) or grafting (2), in addition to retroperitoneal
lymphatic ligation in patients who had a large lymphatic
channel (2-3 mm) that was acceptable for microanastomo-
sis. Three high-risk (20%) patients received a peritoneove-
nous shunt, and one (7%) patient had a hysterectomy for
periuterine lymphangiectasia. All patients undergoing
retroperitoneal mesenteric lymphatic resections or lym-
phovenous grafting were fed 60 g of butter melted in milk
or cream immediately preoperatively to visualize the dilated
lymphatics. Lymphovenous grafting was done in two
patients using a segment of saphenous vein with a compe-
tent valve, and the anastomosis was performed with magni-
fication using an operating microscope (Fig 4).
Eight procedures were performed in six patients for chy-
lothorax, including thoracotomy with decortication and
pleurodesis in two (33%) patients, each of whom underwent
a staged procedure for the contralateral chest. Decortication
and pleurodesis was completed thoracoscopically in 1 (17%)
patient, the thoracic duct was ligated in 2 (33%) patients,
and a thoracic duct cyst was resected in 1 (17%) patient.
Early complications included wound infections in 3
(11%) patients, elevated liver enzymes in 1 (4%), and peri-
toneovenous shunt occlusion with innominate vein occlu-
sion in 1 (4%).
Mean follow-up was 54 months, and median follow-
up was 40 months (range, 1 to 276 months). At most
recent follow-up, two patients (10%) had no symptoms
and 15 (71%) patients were improved. Of the four patients
with lymphovenous anastomosis or grafting, three (75%)
were symptomatically improved. Three patients had post-
operative lymphoscintigraphy confirming improved lym-
phatic transport and diminished reflux. Of the four
patients (19%) who were the same or worse at last follow-
up, all had reported initial improvement postoperatively.
The patient who underwent hysterectomy had subsequent
reaccumulation of chylous fluid after 4 years and required
paracentesis and thoracentesis. Two patients who had
retroperitoneal lymphatic resection reported recurrent
chylous reflux into the limb and perineum at 2 and 7 years,
respectively, but both were able to work despite their
symptoms. A final patient had initial improvement after
lymphovenous anastomosis and retroperitoneal lymphatic
resection but had reaccumulation of pleural effusions and
ascites after 5 years. One (5%) patient who had improve-
ment of chylothorax after 144 months died of cardiac
causes unrelated to PCD.
DISCUSSION
Although primary chylous disorders are rare, loss of
chyle into the peritoneal or thoracic cavity or through chy-
locutanous fistulae of the perineum or legs can have seri-
ous consequences. Chronic loss of chyle leads to anemia,
hypoproteinemia, hypocalcemia and hypolipidemia,
immunocompromise, and malnourishment. Protein-losing
enteropathy may develop, and the large chylous effusions
may also compress the thoracic or abdominal organs.1
Reflux of the chyle and lymph into the legs and genitalia
results in lymphedema.
Chylous ascites is present in as many as one in 50,000
to 100,000 hospital admissions, although these are most
frequently secondary to malignancy, trauma, or infection.9
Primary chylous disorders are usually caused by congenital
lymphangiectasia, sometimes with concomitant obstruc-
tion, agenesis, hypoplasia, or disruption of the thoracic
duct, cisterna chyli, and thoracic or intestinal lymph-
atics.4,10 Chyle will reflux in the dilated, abnormal, tortu-
ous lymphatics as a result of valvular incompetence.
Depending on the sites of the dilated lymphatics and
lymphatic disruption, patients may present with chylous
ascites, chylothorax, chyloptysis, chylopericardium, chy-
luria, or chylous reflux into the scrotum, vagina, labia, per-
ineum, lower extremities, mesentery, or intestine.2,4,10,11
Rare sites of chylous effusions include the pericardial sac
or the joints.12
The diagnosis of primary lymphangiectasia is based on
symptoms and diagnostic imaging. Leakage of milky fluid
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Fig 4. Surgical treatment for lymphedema and chylous effusions
caused by primary chylous disorders.
from cutaneous vesicles in patients with lymphedema
should raise suspicion of chylous reflux. Patients may pre-
sent with yellow nail syndrome, with clinical features of
yellow discoloration of the fingernails often associated
with bronchiectasis, pleural effusion, sinusitis, chylous
ascites, and mesenteric lymphangiectasia. The diagnosis of
pulmonary lymphangiomyomatosis is made in patients
with chylothorax who also have a large number of dilated
lymphatics in the mediastinum and lungs on CT scan.
Paracentesis or thoracentesis will confirm the diagno-
sis of chylous effusion. The aspirated fluid is milky in
appearance and contains lipoproteins.13 In patients with
PCDs, the following blood tests are appropriate: serum
protein, albumin, triglyceride, cholesterol, calcium, and
hemoglobin levels.4 Lymphocytes and immunoglobulins
may also be lost with chylous effusions.6,14
Diagnostic imaging should include CT scan or MRI to
exclude underlying malignancy, aid with the diagnosis of
lymphangiectasia and lymphangiomyomatosis, and confirm
the presence or absence of pericardial or pleural effusions.
Lymphoscintigraphy is performed by injecting technitium-
99m labeled Sb2-S3 colloid or labeled human albumin into
the interdigital space of the foot or hand. The nonaffected
limb should be injected first, because reflux of the colloid
through the incompetent retroperitoneal and pelvic lym-
phatics is well seen on 3-hour and 6-hour imaging.
Accumulation of the radiolabeled isotope can be observed
in lymph vessels, nodes, abdomen, or chest, or reflux down
the contralateral extremity may be found. By employing
semiquantitative transport index, a 92% sensitivity and
nearly 100% specificity can be achieved in diagnosing lym-
phedema.5,15,16 As lymphoscintigraphy is a functional
study, we perform contrast lymphangiography to define
lymphatic anatomy and the site of lymphatic leak. Patients
with lymphangiectasia tolerate lymphangiography much
better than those with occlusive lymphatic lesions. Two
thirds of our patients underwent lymphangiography, and
this study is especially important when lymphovenous
grafting is anticipated or to localize chylous leak before
resection of lymphatics.7,17 Medical management is aimed
at controlling the production of chyle by use of an MCT
diet or, possibly, parenteral nutrition.13,18,19 Diuretics are
administered to decrease formation and increase reabsorp-
tion of chylous effusions. In addition to nutritional man-
agement, serial paracentesis or thoracentesis may be
required, as may lower-limb compression for symptomatic
control. Although these are only palliative measures,
patients may be controlled adequately. Four of the 14
patients in our series were adequately treated with medical
management alone, although follow-up in this group was
poor. Half of the six patients followed long-term were the
same or worse. In many cases of PCD, surgical interven-
tion is the only option to provide long-term improvement.
Surgical treatment should be considered in low-risk
patients with significant symptoms such as malnourish-
ment, chylous reflux, or chylocutaneous fistulae.
Surgical exploration of chylous ascites is performed after
a fatty meal is ingested. Ruptured lymphatics have to be
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oversewn, ligated, or clipped, and chylous cysts should be
excised.9,13,20 Adjunctive sclerotherapy with tetracycline is
done. Occasionally, bowel resection is performed if large
mesenteric lymphatics are localized to one segment.
Servelle3 has the largest series of 55 patients with this proce-
dure with durable results in most patients. In a series of 19
patients by Kinmonth,12 with ligation of the retroperitoneal
lymphatics for chylous reflux to the limbs and genitalia, per-
manent cure was achieved in five patients, and alleviation of
symptoms, frequently after several operations, was achieved
in 12 patients. No improvement or failure was noted in only
two cases. Of the four patients in our series with same or
worse symptoms after retroperitoneal and mesenteric lym-
phatic resection, lymphovenous anastomosis, or hysterec-
tomy, each patient had initial improvement and recurrence
of symptoms between 2 and 7 years postoperatively.
Frequently, several well-defined abdominal fistulae are
identified. However, if the mesenteric lymphatic trunks are
fibrosed, aplastic, or hypoplastic, and exudation of the
chyle is the main source of the ascites, the likelihood of sur-
gical cure is low. In these patients, recurrence of chylous
ascites is frequent and the patient may require a peritoneal-
venous shunt.21,22 All three of our patients had passive
(LeVeen, Becton Dickinson & Co, Rutherford, NJ)
shunts, but treatment of chylous ascites with active shunts
may be considered. Results with peritoneal-venous shunts
have been mixed, and failure may occur as a result of shunt
occlusion.23 In Browse et al’s24 experience with nine peri-
toneal-venous shunts, all became occluded within 3 to 6
months after insertion. Of the three patients in this series
undergoing a peritoneovenous shunt (LeVeen shunt), one
(33%) patient had occlusion with concomitant innominate
vein occlusion. However, based on this single patient, we
do not recommend standard anticoagulation therapy for all
shunt patients. We have used the passive shunts based on
the preference to avoid the pump chamber of active shunts
that may become clogged, but this small series cannot sup-
port or refute that preference.
Chylothorax may occur from thoracic lymphangiecta-
sia, with or without thoracic duct obstruction, or sec-
ondary to chylous ascites passing through the diaphragm.
In the latter group, control of the chylous ascites is the
treatment.25 Preoperative lymphangiography may localize
the site of the chylous fistula or document occlusion of the
thoracic duct. Optimal treatment is surgical pleurodesis,
either with video-assisted thoracoscopy (VATS) or open
thoracotomy, with excision of the parietal pleura.26 In this
series, eight procedures for chylothorax all had excellent
early results. Although earlier procedures were done
through an open thoracotomy, the less invasive VATS may
be considered. Difficult-to-manage chylothorax may
require a pleuroperitoneal shunt, or Denver pleuroperi-
toneal shunt (Codman, Johnson & Johnson, Piscataway,
NJ), although no patients with PCD in our series required
this intervention.27,28 Interesting new techniques for man-
agement of chylothorax have been reported in recent liter-
ature. A percutaneous technique of catheterization and
embolization of the thoracic duct was reported in 11
patients with a 45% technical success rate.29 The treatment
of postoperative chylothorax with intrapleural fibrin glue
was also published and may be indicated in recurrent chy-
lothorax after VATS lymphatic ligation.30
When the upper thoracic duct is occluded, thoracic duct-
azygos vein anastomosis can be attempted to reconstruct the
duct and improve lymphatic transport. If occlusion of the
entire duct is documented on contrast lymphangiography,
anastomosis is not possible. Through a right posterolateral
thoracotomy, an anastomosis between the lower thoracic
duct and the azygos vein is performed in an end-to-end fash-
ion, with 8-0 or 10-0 nonabsorbable interrupted sutures and
magnification using loupes or the operating microscope.
Only a few patients with this operation have been
reported,12,31 and we have performed this operation in two
patients. Browse31 reported two successes in three patients
who underwent thoracic duct reconstruction. However,
Kinmonth12 performed this procedure in two patients and
concluded that the anastomosis alone is not effective for
decompressing the thoracic duct; ligation of the abnormal
mediastinal lymphatics and oversewing of the sites of the lym-
phatic leak are also necessary.
In conclusion, PCDs are rare, and symptoms are
caused by reflux or by disruption of the dilated lymphat-
ics. More than half of the patients with PCDs will require
surgical treatment, and treatment is guided by clinical pre-
sentation and diagnostic evaluation with lymphoscintigra-
phy and lymphangiography. Contrast lymphangiography
determines anatomy, confirms lymphangiectasia and the
site of the lymphatic leak, and is helpful for planning sur-
gical treatment. Although the surgical intervention for
PCDs may be technically demanding, major complications
are rare. All patients had initial benefit postoperatively, and
two thirds of patients demonstrated durable clinical
improvement after surgical treatment.
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Dr Seshadri Raju (Jackson, Miss). Dr Harris, Professor
Ruckley, members and guests. I want to congratulate Dr Noel for
a very nice presentation. The senior author, Dr Peter Gloviczki,
has had a very long interest in the surgical approach to these com-
plex problems.
In this paper, Dr Noel and colleagues have presented a review
of 35 cases of primary chylous disorders or PCD. Most patients
with PCD die in childhood, and only a few survive or manifest the
disorder later in life. This is an astounding collection of a very rare
entity and is possible only because Mayo is a worldwide referral
center and has known expertise in this area. Secondary chylous
disorders usually due to surgical or other trauma are less rare.
Even so, most of us see only a dozen or so cases in a lifetime, so
this collection of cases is very valuable and will serve as a reference
on the topic for some time to come.
The authors have done an excellent job of summarizing the
clinical features and treatment of an entity with widespread organ
involvement, even though the underlying pathology is a single-
system disorder. The manuscript is very well referenced, and I rec-
ommend it highly to anyone interested in the topic. I have a few
questions.
Traditional lymphangiography was used to define the
anatomy in some cases in this long experience covering a quarter
century. Is it still necessary today, especially in the context of the
current availability of antimony, sulfur colloid isotopes under pro-
tocol or alternatively human serum albumin conjugates? Is
ethiodol being used or the old lipiodol? Was the cutdown used for
the procedure a problem? My memory with this technique is that
the cutdown site can be more of a problem with healing and
infection than the primary disease.
Next, what is the preferred antibiotic regimen today in cases
where it is indicated? It has always surprised me that infections in
the abdominal or chest cavity are relatively rare in secondary chy-
lous disorders due to the high immunoglobulin content. Does
that hold true for PCD as well? Finally, it is clear from the manu-
script even though it did not come through in the presentation,
that conservative treatment for this condition is a loser. Would you
recommend that we refer these cases directly for surgery rather
than subject them to an initial period of fruitless medical therapy?
I want to thank the Society for allowing me to discuss this
paper.
Dr Audra A. Noel. Thank you, Dr Raju. First, to address the
issue of lymphangiography, we do not use lipiodol. We use
ethiodol now. Certainly, the presence of infections following lym-
phangiography at the cutdown site is a big issue, which is why we
really cannot obtain postoperative lymphangiography in these
patients. Therefore, our follow-up is based purely on clinical find-
ings and the patients’ clinical success because we have no postop-
erative imaging in those patients.
Antibiotics are needed for cellulitis in the limb with reflux
and usually a cephalosporin which covers skin microbials is ade-
quate. We have not seen a lot of primary infections within the
chylous ascites or the chest unless they have been instrumented,
such as the placement of a LeVeen shunt. Then, the abdomen or
chest fluid may become infected because, as you said, of the high
content of immunoglobulin.
Conservative therapy is probably still the treatment of choice
for patients who are extremely high-risk and are malnourished, and
that would still be our first option in severely ill patients. But cer-
tainly if there is a lymphatic lesion that can be corrected surgically
based on preoperative imaging, operation should be recommended.
Dr B. B. Lee (Seoul, South Korea). I do congratulate you for
the excellent results. I really admire them. Two questions. I saw
one case you handled with a thoracic ductal ligation. What was
the eventual outcome for that case? The second question is, how
much will a septic episode affect your surgical indication? I would
like to make two comments. One, still the conservative way is the
best way, but I believe the right time for the right treatment
should include peritoneal jugular shunt which is amazingly work-
ing better than anybody believes, even though sepsis is sort of an
enigma on this shunt procedure, especially for chyloascites. The
second thing is, you really should denounce the casual approach
to ligate thoracic duct or cisterna chyli, because these days we
consider this obscure disease as a candidate for the intestinal
transplant. As a matter of fact, the second transplant we did in
Seoul last year was this primary lymphangiectasia combined with
AV telangiectatic change in the small bowel, so I would like to
discourage that casual ligation, though people still prefer to use it.
Dr Noel. Fortunately, we have had two patients with ligation
of the thoracic duct and both of them had clinical improvement.
Actually, one patient had resolution of both chylous ascites and
chylothorax after thoracic duct ligation.
In regard to your question of sepsis, we would not pursue
surgical treatment if the patient had acute sepsis.
Dr Lee. Because I am sure a lot of people know about the new
role of OK-432 (Picibanil), Japanese-made scleral agent and the
results are supposed to be excellent but due to the sepsis rate it
still has a problem. We are wondering whether you consider this
sepsis-related treatment will be one of a surgical indication to take
aggressive approach.
Dr Noel. We do not have any experience with that product.
Dr Kevin Burnand (London, England). We have a similar size
experience to yours at St Thomas. We would feel that almost all
patients do need some form of surgical treatment. We think that
the diagnosis is important by aspirating and proving that you have
chylomicrons present within the aspirate. You did not comment on
that. Do you always do that? We think that repeated aspiration is
dangerous because you can drop the protein very low and we think
that should be avoided. We actually very firmly believe that you
should not do thoracoscopic pleurodesis because we have had
recurrences that have occurred after thoracoscopic pleurodesis,
whereas we had none after surgical pleurodesis and that seems cura-
tive. For the belly, we have had poor results with the shunts because
the shunts have tended to block as a consequence of the high pro-
tein content present within it and I would like you to comment on
that. We told patients they may develop further swelling in their
legs, and I wonder if you treat the leg swelling in these patients?
Since pleurodesis and pleurectomy is such a good treatment for
thoracic, why would you favor thoracoscopic treatment?
Dr Noel. As far as the thoracoscopic approach, we have only
had one patient who did have success, but I agree that open tho-
racotomy with pleurodesis remains the optimal operation.
Our one patient did have an occluded shunt, possibly from
high protein content of fluid or venous thrombosis. Most of the
literature on the LeVeen shunt includes all patients with all reasons
for ascites. Patients with chylous ascites probably do not do as well
with shunts, but for some patients it is the only option. The
patients in whom we have used shunts were quite malnourished
and would not have tolerated retroperitoneal lymphatic resection.
As far as the lower-extremity swelling, one thing I did not
comment on in the talk is that all patients get compression treat-
ment pre- and postoperatively.
Thank you.
Dr Peter Gloviczki. I would like to make one final comment.
I agree with Dr Lee very much, that ligation of the thoracic duct
may not be beneficial and should be avoided in primary lym-
phangiectasia. Indeed, the chyle leak is frequently not in the duct
but in larger intercostals or diaphragmatic lymphatic collaterals,
so ligation of the duct would not be effective. If there is proximal
thoracic duct occlusion, thoracic duct to azygos vein anastomosis
can be performed through a right thoracotomy, together with
open pleurodesis. The size of the duct in such patients is 3 to 4
millimeters. We did it in two patients, with good result.
DISCUSSION
